Myeloproliferative neoplasms: Histopathological and molecular pathological diagnosis;Myeloproliferative Neoplasien: Histopathologische und molekularpathologische Diagnostik

Pathologe

Volumn 33, Issue 6, 2012, Pages 508-517

  Hussein, K ^a   Busche G ^a   Schlue, J ^a   Lehmann, U ^a   Kreipe, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cell proliferation; Growth factors; Leukemia; Molecular markers; Myeloproliferative disorders

Indexed keywords

TUMOR MARKER;

BLAST CELL CRISIS; BONE MARROW; BONE MARROW EXAMINATION; CANCER STAGING; CELL TRANSFORMATION; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; GENETIC MARKER; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MOLECULAR DIAGNOSIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVIEW;

BLAST CRISIS; BONE MARROW; BONE MARROW EXAMINATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; DNA MUTATIONAL ANALYSIS; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR DIAGNOSTIC TECHNIQUES; MYELODYSPLASTIC-MYELOPROLIFERATIVE DISEASES; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 84867925020     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-012-1651-3     Document Type: Article

References (52)

1. Beer PA, Delhommeau F, LeCouédic JP et al (2010) Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115:2891-2900
2. Bock O, Muth M, Theophile K et al (2009) Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis. Br J Haematol 146:510-520
3. Brousseau M, Parot-Schinkel E, Moles MP et al (2010) Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology 56:758-767
4. Buhr T, Hebeda K, Kaloutsi V et al (2012) European Bone Marrow Working Group trial on reproducibility of WHO criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 97:360-365
5. Burkhardt R, Bartl R, Jäger K et al (1986) Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings. J Clin Pathol 39:237-252
6. Bellanné-Chantelot C, Chaumarel I, Labopin M et al (2006) Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 1081:346-352
7. Campbell PJ, Green AR (2006) The myeloproliferative disorders. N Engl J Med 355:2452-2466
8. Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895-2901
9. Cools J, DeAngelo DJ, Gotlib J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214
10. Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6:372-375
11. Delhommeau F, Dupont S, Della Valle V et al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289-2301
12. Dupriez B, Morel P, Demory JL et al (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88:1013-1018
13. Elliott MA, Verstovsek S, Dingli D et al (2007) Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 31:1503-1509
14. Ernst T, Hochhaus A (2012) Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin Oncol 39:58-66
15. Foa P, Iurlo A, Saglio G et al (1991) Chronic neutrophilic leukaemia associated with polycythemia vera: pathogenetic implications and therapeutic approach. Br J Haematol 78:286-288
16. Gangat N, Caramazza D, Vaidya R et al (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392-397
17. Georgii A, Buhr T, Buesche G et al (1996) Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 22(Suppl 1):15-29
18. Hagemeijer A, Plas DC van der, Soekarman D et al (1990) The Philadelphia translocation in CML and ALL: recent investigations, new detection methods. Nouv Rev Fr Hematol 32:83-86
19. Haq AU (1990) Transformation of polycythemia vera to Ph-positive chronic myelogenous leukemia. Am J Hematol 35:110-113
20. Harrison CN, Bareford D, Butt N et al (2010) Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 149:352-375
21. Harrison CN, Campbell PJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33-45
22. Higuchi T, Oba R, Endo M et al (1999) Transition of polycythemia vera to chronic neutrophilic leukemia. Leuk Lymphoma 33:203-206
23. Hoppin EC, Lewis JP (1975) Polycythemia rubra vera progressing to Ph-positive chronic myelogenous leukemia. Ann Intern Med 83:820-823
24. Hussein K, Bock O, Ballmaier M et al (2007) Familial polycythemia vera with non-germline JAK2(V617 F) mutation sparing the abnormal and clonal granulopoiesis. Leukemia 21:2566-2568
25. Hussein K, Bock O, Seegers A et al (2007) Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 109:4106-4107
26. Hussein K, Bock O, Theophile K et al (2008) Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 22:1059-1062
27. Hussein K, Bock O, Theophile K et al (2009) JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 37:1186-1193
28. Hussein K, Theophile K, Buhr T et al (2009) Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation. Br J Haematol 145:673-675
29. Iurlo A, Foa P, Maiolo AT et al (1990) Polycythemia vera terminating in chronic neutrophilic leukemia: report of a case. Am J Hematol 35:139-140
30. James C, Ugo V, Le Couédic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148
31. Jantunen E, Nousiainen T (1991) Ph-positive chronic myelogenous leukemia evolving after polycythemia vera. Am J Hematol 37:212
32. Kreipe H, Hussein K, Göhring G, Schlegelberger B (2011) Progression of myeloproliferative neoplasms to myelofibrosis and acute leukaemia. J Hematopathol 4:61-68
33. Kreipe H, Jaquet K, Felgner J et al (1991) Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 78:1814-1817
34. Kreipe HH, Beham-Schmid C, Dirnhofer S et al (2011) Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. [e-Letter], Blood http://bloodjournal. hematologylibrary.org/content/117/21/5710.long/reply#bloodjournal-el-3427). Zugegriffen: 23. Dez. 2011
35. Lugassy G, Farhi R(1989) Chronic neutrophilic leukemia associated with polycythemia vera. Am J Hematol 31:300-301
36. Mirza I, Frantz C, Clarke G et al (2007) Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med 131:1719-1724
37. Muth M, Engelhardt BM, Kröger N et al (2011) Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia. Ann Hematol 90:33-40
38. Pardanani A, Lasho TL, Finke CM et al (2010) IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 24:1146-1151
39. Pardanani A, Lasho TL, Finke CM, Tefferi A (2011) Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol 86:701-702
40. Pietra D, Li S, Brisci A et al (2008) Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617 F)-negative myeloproliferative disorders. Blood 111:1686-1689
41. Primo D, Sanchez ML, Espinosa AB et al (2006) Lineage involvement in chronic myeloid leukaemia: comparison between MBCR/ABL and mBCR/ABL cases. Br J Haematol 132:736-739
42. Skoda RC (2010) Hereditary myeloproliferative disorders. Haematologica 95:6-8
43. Spivak JL, Silver RT (2008) The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis: an alternative proposal. Blood 112:231-239
44. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haemtopoietic and lymphoid tissues. Lyon, IARC, Lyon
45. Tan PT, Wei AH (2011) The epigenomics revolution in myelodysplasia: a clinico-pathological perspective. Pathology 43:536-546
46. Tefferi A, Vainchenker W (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29:573-582
47. Theocharides A, Boissinot M, Girodon F et al (2007) Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110:375-379
48. Thiele J, Kvasnicka HM, Facchetti F et al (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128-1132
49. Thiele J, Kvasnicka HM, Müllauer L et al (2011) Essential thromobcythemia versus early primary myelofibrosis - a multicenter study to validate WHO classification. Blood 117:5710-5718
50. Thoennissen NH, Krug UO, Lee DH et al (2010) Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 115:2882-2890
51. Verstovsek S, Kantarjian HM, Estrov Z et al (2012) Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood
52. Wilkins BS, Erber WN, Bareford D et al (2008) Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 111:60-70